Rahul Adakmol

Chief Operating Officer, International Operations

Bharat Serums and Vaccines Limited · Full-time

Advent International, a leading global Private Equity firm, acquired controlling stakes in Bharat Serums and Vaccines Ltd (BSV) for USD ~0.5 Bn in February 2020. Joined BSV’s management as COO in March 2020 to transform the business. Worked closely with the PE stakeholders and the Board in the value creation. Advent exited in October 2024 at 3X valuation of USD ~1.6 bn. Currently working with the new (Mankind Pharma) Board to manage the integration process and build Mankind’s large scale international business. • Built successfully USD ~100+ mn Branded Specialty International Business focusing on IVF, Women Health and Critical Care; with High Profitability (50+% EBITDA) and High Growth (5Yr CAGR 25%). o Transformed successfully a fragmented, low growth business in 4 Yrs despite covid uncertainties. o Prioritized markets, brands, portfolio to bring focus. Identified Global IVF as strategic differentiation. o Built differentiated portfolio through R&D prioritization, In-licensing and cross border M&A o Built a team of highly capable and motivated professionals to deliver consistent performance. o Established GTM (Go-to-market) with feet on ground in 15 countries, with 250+ field force rapidly deployed with a repeatable playbook. Substantial scale up of IVF, Women health (35% CAGR). o Prioritized the investments to deliver growth with tight opex management and delivered 50+% EBITDA. • Core member of the team engaged for the Exit Process which managed the exit with record USD 1.6bn valuation o Represented BSV in 30+ investor-management meetings, pre-NBO, post-NBO and during Due Diligence to position BSV as an attractive investment option; managed the stakeholders and built comfort among potential investors about the business performance, health and future outlook.

Vice President – Head Business Development for Branded Markets – India and Emerging Markets

Dr. Reddy's Laboratories · Full-time

• Led Business Development (M&A, In-licensing and Strategic Alliances) for Dr. Reddys’ Branded Business (USD 800+ in size) which geographically includes India and Emerging Markets (RCIS, APAC, LATAM, Africa). Having experience of successfully concluding deals with Yr 5 revenue potential of USD 250+ mn. o Successfully concluded two large scale acquisitions – UCB’s multispecialty business in India for Rs 800 Cr; Wockhardt’s branded business in India for Rs. 1850 Cr. o 30+ Licensing deals across therapies and geographies - India and Emerging markets. o Assessed ~50+ M&A targets, submitted 10+ NBOs and conducted 10+ cross border Due Diligences with cumulative potential investments of USD 1.5 bn+ • Led Sales and Marketing for Prolia Division, created for commercializing in India, Amgen’s Global NBE – Prolia (Denosumab) with specialty team, targeting top Orthopedics, Spine Surgeons, Endocrinologists, Rheumatologists. • Recipient of Chairman's Excellence Award for demonstrating outstanding leadership and creating exceptional organizational impact. This award is given to top 5 leaders in Dr. Reddy’s. • Led Dr. Reddy’s Strategic Business Initiative in Nutritions. Designed unique portfolio for Diabetes.

Director and Senior Director India Business– Portfolio; Business Development & M&A

Dr. Reddy's Laboratories · Full-time

• Core member of India Domestic Business Council. Part of the strategic planning and execution; Contributed to 50% of business growth through 30+ licensing deals with global partners and M&A • Largest Contribution by a team lead - ~45% (Rs. ~450 Cr annual revenue) - to the growth of branded business in India. Enabled substantial scale up of specialty businesses – Oncology, Neurology, Critical Care, ENT, Dermatology. • Led Strategic Alliance with Amgen, UCB, AZ in India. The alliance with Amgen has 6 global assets – Repatha, Kyprolis, Blincyto, Prolia, Xgeva, Vectibix. Alliance with UCB has 3 global brands – Briviact, Keppra, Siezgard. Acquisitions: • Lead Negotiator and Integrator for acquisition of UCB Pharma’s business in India for Rs 800 Cr.

Corporate Planning, Risk Management, EA to the MD

Dr. Reddy's Laboratories · Full-time

• Implemented Enterprise Risk Management (ERM) framework pioneered by Ernst and Young for entire company. • Driven Strategic planning exercise for mapping growth priorities; Corporate performance management for the MD

Asst Manager

Reliance Industries Ltd · Full-time

• Member of Special Task Force, for Reliance Jamnagar Refinery which is the world’s largest Grass-root refinery. This group handles technical and techno-economical projects to create substantial value for the refinery. • Inventory Benchmarking: identified potential yearly savings of US$ 9 million through efficient inventory management; De-bottlenecking of Capacities: using Simulation Techniques, identified production stretch, up to 145% of design.